🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 89 of 116

  1. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutamide film coated tablets 80 mg, Manufactured for Sun Pharmaceutical Industries Limited, India with XTANDI (Enzalutamide) 80 mg film coated tablets, Made by: Patheon Inc., 2100 Syntex Court, Mississauga, Ontario – Canada, Imported and registered by: Astellas Farma Brasil Importação e Distribuição de Medicamentos Ltda., São Paulo-SP, Brazil, in healthy adult, male subjects

    Lacuna Pharma Pty Ltd

    Prostate cancer

    phase 1 other active

    1 trial

  2. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  3. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec® (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo – SP, CNPJ: 56.994.

    Lacuna Pharma Pty Ltd

    Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid Leukemia

    phase 1 other active

    1 trial

  4. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code

    Lacuna Pharma Pty Ltd

    chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia

    phase 1 other active

    1 trial

  5. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  6. An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

    BioNTech SE

    Metastatic melanoma

    phase 1 other active

    1 trial

  7. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  8. An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  9. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  10. Anti-CD123 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    AML (Acute Myeloid Leukemia)

    phase 1 small molecule active

    1 trial

  11. Anti-CD19 Universal CAR-T Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  12. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  13. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  14. Anti-CD5 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    T-ALL/Lymphoma

    phase 1 mab active

    1 trial

  15. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  16. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  17. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  18. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  19. Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

    Takeda

    Metastatic Adenocarcinoma of the Colon or Rectum

    phase 1 mab completed

    1 trial

  20. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  21. Anti-SEMA4D Monoclonal Antibody VX15/2503

    VACCINEX, INC.

    Colon Carcinoma Metastatic in the Liver

    phase 1 mab completed

    1 trial

  22. Arm 1 cemiplimab

    Regeneron UK Limited

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  23. Arsenic trioxide

    Teva Pharma GmbH

    Chronic Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  24. Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients

    Formycon AG

    Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection

    phase 1 other active

    1 trial

  25. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  26. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Endometrial Cancer

    phase 1 small molecule active

    1 trial

  27. Atovaquone Oral Suspension

    United Therapeutics Europe Ltd

    Locally Advanced Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  28. Atu027

    Silence Therapeutics plc

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  29. Autologous Natural Killer Cell Therapy

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  30. Autologous tumor-infiltrating lymphocyte cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 mab terminated

    1 trial

  31. Autologous γδT cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  32. Axatilimab

    Syndax Pharmaceuticals

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  33. Azenosertib

    Zentalis Pharmaceuticals

    Solid Tumor

    phase 1 small molecule active

    2 trials

  34. Azenosertib

    Zentalis Pharmaceuticals

    Osteosarcoma

    phase 1 small molecule completed

    1 trial

  35. BAY2965501

    Bayer HealthCare AG

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  36. BBO-10203

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  37. BBO-11818

    BridgeBio Oncology Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  38. BBO-8520

    BridgeBio Oncology Therapeutics

    Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  39. BBP-398

    BridgeBio Oncology Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  40. BBP-398 (Formerly known as IACS-15509)

    BridgeBio Oncology Therapeutics

    Tumor, Solid

    phase 1 small molecule terminated

    1 trial

  41. BBP-398 with nivolumab

    BridgeBio Oncology Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  42. BC006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumors (Including GCTTS)

    phase 1 small molecule active

    1 trial

  43. BCA101

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  44. BDB001 (EIK1001)

    Eikon Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    2 trials

  45. BDB018

    Eikon Therapeutics

    Tumor, Solid

    phase 1 small molecule completed

    1 trial

  46. BDC-3042

    Bolt Biotherapeutics

    Triple Negative Breast Cancer

    phase 1 small molecule terminated

    1 trial

  47. BDTX-189

    Blackmores Limited

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  48. BEL-X-HG

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.